Current allergen immunotherapy market situation – September 2022

Adam Górka; Rafał Pawliczak

doi:10.5114/pja.2022.122004

eISSN: 2391-6052
ISSN: 2353-3854

Alergologia Polska - Polish Journal of Allergology

Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2022
vol. 9

Send email

Copy url:

abstract:

Review paper

Current allergen immunotherapy market situation – September 2022

Adam Górka

¹

,

Rafał Pawliczak

¹

Zakład Immunopatologii, Wydział Lekarski, Uniwersytet Medyczny, Łódź, Polska

Alergologia Polska – Polish Journal of Allergology 2022; 9, 4: 246–249

DOI: https://doi.org/10.5114/pja.2022.122004

Online publish date: 2022/12/09

View full text Get citation

PlumX metrics:

Immunotherapy pharma market has been still increasing in Poland in the last 20 years. The number of practicing allergist increased by 10 fold, enhancing access to allergy healthcare. Internal and external factors influenced the patients’ access to the specific immunotherapy. During last two years a vast decrease in the number of patient undergoing allergen specific immunotherapy was noted. This may affect public health in the near feature.

keywords:

Current allergen immunotherapy market situation – September 2022

Adam Górka 1 , Rafał Pawliczak 1

pharma market, allergen immunotherapy

Adam Górka

¹

,

Rafał Pawliczak

¹